Parkinson's disease: Progression and mortality in the L-DOPA era

被引：0
|
作者：
DiRocco, A
Molinari, SP
Kollmeier, B
Yahr, MD
机构：
来源：
PARKINSON'S DISEASE | 1996年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：3 / 11
页数：9
相关论文
共 50 条
  • [21] L-dopa impairs associative learning in Parkinson's disease
    Shohamy, D
    Myers, CE
    Onlaor, S
    Gluck, MA
    [J]. JOURNAL OF COGNITIVE NEUROSCIENCE, 2002, : 84 - 84
  • [22] The effects of L-Dopa on attention in Parkinson's disease and Parkinson's dementia patients
    Molloy, S
    McKeith, IG
    Burn, D
    Wesnes, KA
    [J]. JOURNAL OF PSYCHOPHARMACOLOGY, 2004, 18 (03) : A51 - A51
  • [23] The effects of L-dopa on attention in Parkinson's disease and Parkinson's dementia patients
    Molloy, S.
    McKeith, I. G.
    Burn, D.
    Wesnes, K. A.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2006, 248 (1-2) : 294 - 294
  • [24] The relation of serum uric acid levels with L-Dopa treatment and progression in patients with Parkinson's disease
    Vieru, Eugeniu
    Koksal, Ayhan
    Mutluay, Belgin
    Dirican, Ayten Ceyhan
    Altunkaynak, Yavuz
    Baybas, Sevim
    [J]. NEUROLOGICAL SCIENCES, 2016, 37 (05) : 743 - 747
  • [25] MitoPark mice mirror the slow progression of key symptoms and L-DOPA response in Parkinson's disease
    Galter, D.
    Pernold, K.
    Yoshitake, T.
    Lindqvist, E.
    Hoffer, B.
    Kehr, J.
    Larsson, N. -G.
    Olson, L.
    [J]. GENES BRAIN AND BEHAVIOR, 2010, 9 (02) : 173 - 181
  • [26] l-dopa treatment duration versus Parkinson's disease progression: The dorsal-ventral divide
    Belujon, Pauline
    Grace, Anthony A.
    [J]. MOVEMENT DISORDERS, 2013, 28 (02) : 120 - 121
  • [27] The relation of serum uric acid levels with l-Dopa treatment and progression in patients with Parkinson’s disease
    Eugeniu Vieru
    Ayhan Köksal
    Belgin Mutluay
    Ayten Ceyhan Dirican
    Yavuz Altunkaynak
    Sevim Baybas
    [J]. Neurological Sciences, 2016, 37 : 743 - 747
  • [28] The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease
    Heikkinen, H
    Nutt, JG
    LeWitt, PA
    Koller, WC
    Gordin, A
    [J]. CLINICAL NEUROPHARMACOLOGY, 2001, 24 (03) : 150 - 157
  • [29] Conversion of L-dopa to Extended Release L-dopa (Rytary®) in Patients with Fluctuating Parkinson's Disease: Predictors of Dose
    Ondo, William
    Coss, Pablo
    Christie, Melissa
    Pascual, Belen
    [J]. JOURNAL OF PARKINSONS DISEASE, 2019, 9 (01) : 153 - 156
  • [30] L-DOPA in Parkinson's Disease: Looking at the "False" Neurotransmitters and Their Meaning
    Chagraoui, Abdeslam
    Boulain, Marie
    Juvin, Laurent
    Anouar, Youssef
    Barriere, Gregory
    De Deurwaerdere, Philippe
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (01)
12345